MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

Prostate

Volumn 70, Issue 14, 2010, Pages 1501-1512

  Kojima, Keitaro ^a,b   Fujita, Yasunori ^b   Nozawa, Yoshinori ^b,c   Deguchi, Takashi ^a   Ito, Masafumi ^b  

^a GIFU UNIVERSITY   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c TOKAI GAKUEN UNIVERSITY   (Japan)

Author keywords

3 untranslated region; Bcl2; Chemoresistance; HuR; MiRNA; SIRT1

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; CISPLATIN; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; HORMONE; HUR PROTEIN; LIPOSOME; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 34A; PACLITAXEL; PROTEIN BCL 2; SIRTUIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIRN34 MICRORNA, HUMAN; PRIMER DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RNA;

3' UNTRANSLATED REGION; ARTICLE; CELL STRAIN PC3; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BLOOD; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DAUNORUBICIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; MALE; MICRORNAS; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956989411     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21185     Document Type: Article

References (36)

1. Pienta KJ, Smith DC,. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2005; 55 (5): 300 -318; quiz 305-323.
2. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34 -45.
3. Berry W, Eisenberger M,. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10 (Suppl 3): 30 -39.
4. Kingston DG, Bane S, Snyder JP,. The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle 2005; 4 (2): 279 -289.
5. Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH,. Gene expression profiling revealed novel mechanism of action of taxotere and furtulon in prostate cancer cells. BMC Cancer 2005; 5: 7.
6. Impens F, Van Damme P, Demol H, Van Damme J, Vandekerckhove J, Gevaert K,. Mechanistic insight into taxol-induced cell death. Oncogene 2008; 27 (33): 4580 -4591.
7. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F,. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51 (18): 4845 -4852.
8. Caldas C, Brenton JD,. Sizing up miRNAs as cancer genes. Nat Med 2005; 11 (7): 712 -714.
9. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6 (11): 857 -866.
10. Bushati N, Cohen SM,. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175 -205.
11. Esquela-Kerscher A, Slack FJ,. Oncomirs MicroRNAs with a role in cancer. Nat Rev Cancer 2006; 6 (4): 259 -269.
12. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG,. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282 (32): 23716 -23724.
13. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C,. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5: 24.
14. Ozen M, Creighton CJ, Ozdemir M, Ittmann M,. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27 (12): 1788 -1793.
15. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P,. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009; 69 (8): 3356 -3363.
16. Hermeking H,. p53 enters the microRNA world. Cancer Cell 2007; 12 (5): 414 -418.
17. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H,. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6 (13): 1586 -1593.
18. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT,. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26 (5): 745 -752.
19. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M,. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26 (5): 731 -743.
20. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D,. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009; 388 (1): 35 -40.
21. Welch C, Chen Y, Stallings RL,. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26 (34): 5017 -5022.
22. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y, Deguchi T, Ito M,. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377 (1): 114 -119.
23. Michan S, Sinclair D,. Sirtuins in mammals: Insights into their biological function. Biochem J 2007; 404 (1): 1 -13.
24. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A,. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005; 65 (22): 10183 -10187.
25. Jung-Hynes B, Nihal M, Zhong W, Ahmad N,. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284 (6): 3823 -3832.
26. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y, Deguchi T, Ito M,. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 2008; 373 (3): 423 -428.
27. Yamakuchi M, Ferlito M, Lowenstein CJ,. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105 (36): 13421 -13426.
28. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M,. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007; 67 (9): 955 -967.
29. Abdelmohsen K, Pullmann R Jr, Lal A, Kim HH, Galban S, Yang X, Blethrow JD, Walker M, Shubert J, Gillespie DA, Furneaux H, Gorospe M,. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007; 25 (4): 543 -557.
30. Abdelmohsen K, Lal A, Kim HH, Gorospe M,. Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle 2007; 6 (11): 1288 -1292.
31. Kwon HS, Ott M,. The ups and downs of SIRT1. Trends Biochem Sci 2008; 33 (11): 517 -525.
32. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C,. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009; 80 (4-5): 268 -273.
33. Meijerman I, Beijnen JH, Schellens JH,. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 2008; 34 (6): 505 -520.
34. Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD,. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 2000; 3 (2): 66 -75.
35. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Takahashi K,. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008; 9 (2): 167 -174.
36. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R,. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69 (19): 7569 -7576.